MSD Japan Nets 24% Growth in 2022 on Lagevrio, Keytruda; President Wary of Further Re-Pricing

MSD Japan President Kyle Tattle MSD Japan said on April 5 that its 2022 sales climbed 24% over the prior year, buoyed primarily by three key drivers including its COVID-19 pill Lagevrio (molnupiravir) and I/O star Keytruda (pembrolizumab). While Keytruda...read more